Passage Bio, Inc. (PASG)
Develops gene therapies for brain and nervous system diseases.
$4.57-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-20.4%
The outlook
PASG is trading near the bottom of its 52-week range, well below both its 50- and 200-day moving averages, signaling weak near-term momentum. Analyst coverage is bullish on average, with targets implying significant upside from current levels, though the overall StockGlow score leans bearish. The stock reflects the tension between analyst optimism and poor recent price action.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Price targetAvg target +239% vs current price
Analyst price target
~12-month · 2 analysts$15.50average target+239.2% vs now
Now $4.57
Low $8.00High $23.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$14.7M
52-wk high
$20.00
52-wk low
$3.29
50-day avg
$5.20
200-day avg
$8.09
Trailing P/E
—